47 / 100
AltIndex AI Score
Hold
AI Score · 12-mo trend
+4 pts over 3 months0% of NVCR’s tracked signals bullish
FundamentalsBullish
TechnicalsNeutral
Alternative dataNeutral
SentimentNeutral
Price$16.85
Year Range$10.03 – $19.99
Market Cap$2.09B
IndustryMedical & Dental Instruments

What Is NovoCure’s AI Stock Analysis?

NovoCure’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks NovoCure’s momentum in near-real time.

NovoCure (NVCR) has an AltIndex AI Score of 47/100, currently a Hold signal. The AI Score distills NovoCure's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.

NovoCure’s Full AI Analysis

NovoCure is a pioneering company in the field of oncology, specializing in the development of Tumor Treating Fields (TTFields) therapy, a novel approach to cancer treatment. The company's technology utilizes electric fields to disrupt cancer cell division, providing a unique treatment option for patients. Headquartered in Saint Helier, Jersey, NovoCure has been making significant advances in the medical field, garnered by the increasing acceptance and usage of their innovative treatments across various institutions globally.

Fundamental Analysis

The revenue for NovoCure in the last quarter was $184M, representing a 5.47% increase compared to the previous quarter. This growth is particularly important as it demonstrates consistent upward momentum. On a year-over-year basis, the revenue increased by 15.60%, a positive indicator of the company's long-term growth trajectory.

Premium

Keep reading AltIndex’s full AI analysis of NovoCure — the fundamental, technical and alternative-data breakdown and the recommendation.

Sign up to read the full analysis

What’s Driving NVCR’s AI Score?

Fundamentals

Revenue for the last quarter was $184M. This is an increase of 5.47% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 15.60%, suggesting positive year-over-year growth. Net income for the last quarter was $-16M. This is an increase of -77.99% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -60.99%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-11M. This is an increase of -83.31% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -66.51%, suggesting positive year-over-year growth.

See NovoCure’s earnings and insider transactions.

Technicals

Today's stock price is $16.85. This is an increase of 2.81% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 38.00%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $17.60, which is lower than the previous SMA10 of $17.69. This suggests a potential downward trend in price movement. The RSI is 60.5, indicating a neutral condition.

See the full technical analysis and price prediction.

Alternative data

NovoCure has an estimated 51 open positions. This number is down by -7% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at NovoCure is low (an estimate of only 37% of employees have a positive outlook), a concerning sign. Add to that that the business outlook is down by -5% in the last couple of months, an even more concerning trend. NovoCure has an estimate of 27,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.

Explore NovoCure’s job postings, web traffic and app downloads.

Sentiment & social

The sentiment for the stock on various stock forums is neutral. NovoCure has 2,800 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.

Track NovoCure’s market sentiment.

Frequently Asked Questions: NovoCure AI Stock Analysis

NovoCure's AltIndex AI Score is 47/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.

AltIndex's AI Score model rates NovoCure a Hold (47/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.

The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.

AltIndex generates a complete written AI analysis of NovoCure — company overview, fundamentals, technicals and alternative data, with a recommendation. See the NVCR AI Score or sign up to read the full thesis.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.